30. November 2016

Press Release: Zedira receives funding by the German Government for the development of transglutaminase inhibitors for the treatment of diabetic nephropathy



Darmstadt, November, 30th 2016  

Zedira announced today that the BMBF will grant additional 1.5 million Euros funding to the company within the highly competitive SME-Innovative program over the next three years.
The aim of the project is for Zedira to develop small molecule tissue transglutaminase inhibitors that are orally bioavailable. Transglutaminase is considered to be a scientifically validated target in certain fibrotic diseases such as diabetic nephropathy. Kidney injury is one of the most severe complications of diabetes.

The funding will allow Zedira to expand its leadership in low-molecular-weight transglutaminase blockers. In fact, Zedira’s ZED1227 is the first transglutaminase blocker ever to be evaluated in clinical trials for celiac disease, and is currently in phase 1b trials.  Additionally, the core biotech company has recently developed ZED3197, the first drug candidate to target blood coagulation factor XIII (F13, plasma transglutaminase). This compound (a peptidomimetic) has proved to be a potent anticoagulant without prolonging the bleeding time in an animal model of venous stasis and reperfusion.

About Zedira:
The Darmstadt-based biotech company has a focus on transglutaminase-linked conditions in the arena of autoimmunity, fibrotic disease and thrombosis. The company develops, produces and markets specialized reagents and kits for research and development as well as for clinical diagnostics. Zedira is a portfolio company of the German High-Tech Gründerfonds.

Document

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification

Blog  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy